Astrazeneca annual debt-to-equity ratio
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Astrazeneca Debt-to-Equity Ratio Growth & History (AZN)
Astrazeneca's debt-to-equity ratio was 0.65 for fiscal 2025.
View full Astrazeneca company overviewAstrazeneca annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.65 | −0.13 | −17.04% |
| 2024 | 2024-12-31 | 0.78 | 0.02 | +2.41% |
| 2023 | 2023-12-31 | 0.76 | −0.05 | −6.74% |
| 2022 | 2022-12-31 | 0.81 | 0.01 | +0.74% |
| 2021 | 2021-12-31 | 0.81 | −0.54 | −39.99% |
| 2020 | 2020-12-31 | 1.35 | −0.09 | −6.37% |
| 2019 | 2019-12-31 | 1.44 | −0.09 | −6.07% |
| 2018 | 2018-12-31 | 1.53 | 0.34 | +28.79% |
| 2017 | 2017-12-31 | 1.19 | 0.06 | +5.19% |
| 2016 | 2016-12-31 | 1.13 | 0.32 | +38.99% |
| 2015 | 2015-12-31 | 0.81 | — | — |
Astrazeneca quarterly debt-to-equity ratio
Q4.17
Q2.18
Q4.18
Q2.19
Q4.19
Q2.20
Q4.20
Q2.21
Q4.21
Q2.22
Q4.22
Q2.23
Q4.23
Q2.24
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.64 | −0.13 | −16.85% |
| Q1 2026 | 2026-03-31 | 0.72 | — | — |
| Q4 2025 | 2025-12-31 | 0.65 | −0.13 | −17.04% |
| Q3 2025 | 2025-09-30 | 0.71 | — | — |
| Q2 2025 | 2025-06-30 | 0.77 | −0.11 | −12.41% |
| Q4 2024 | 2024-12-31 | 0.78 | 0.02 | +2.41% |
| Q2 2024 | 2024-06-30 | 0.88 | 0.06 | +6.88% |
| Q4 2023 | 2023-12-31 | 0.76 | −0.05 | −6.74% |
| Q2 2023 | 2023-06-30 | 0.82 | −0.02 | −2.77% |
| Q4 2022 | 2022-12-31 | 0.81 | 0.01 | +0.74% |
| Q2 2022 | 2022-06-30 | 0.85 | −0.95 | −52.89% |
| Q4 2021 | 2021-12-31 | 0.81 | −0.54 | −39.99% |
| Q2 2021 | 2021-06-30 | 1.80 | 0.13 | +7.93% |
| Q4 2020 | 2020-12-31 | 1.35 | −0.09 | −6.37% |
| Q2 2020 | 2020-06-30 | 1.67 | 0.16 | +10.51% |
| Q4 2019 | 2019-12-31 | 1.44 | −0.09 | −6.07% |
| Q2 2019 | 2019-06-30 | 1.51 | −0.05 | −3.07% |
| Q4 2018 | 2018-12-31 | 1.53 | 0.34 | +28.79% |
| Q2 2018 | 2018-06-30 | 1.56 | — | — |
| Q4 2017 | 2017-12-31 | 1.19 | — | — |
Astrazeneca debt-to-equity ratio trends
Over the last five fiscal years, Astrazeneca's debt-to-equity ratio decreased from 1.35 to 0.65, a change of −0.70. The latest reported quarter, Q2 2026, shows 0.64.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Astrazeneca source filings ↗Community posts
AstraZeneca receives US accelerated approval for Etcamah in a defined breast-cancer setting
AstraZeneca announced US accelerated approval of Etcamah on 7 September 2026. Approved setting Camizestrant, combined with a CDK4/6 inhibitor, is approved for adults with HR-positive, HER2-negative locally advanced or metastatic breast canc ...